Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc has demonstrated a significant enhancement in its pipeline prospects, particularly with the increased probability of FDA approval for bitopertin, now at 100%, following strong trial results showcasing its efficacy in reducing PPIX. Additionally, the company anticipates notable revenue growth, estimating sales of $35 million in 2026, escalating to $615 million by 2029, driven by an updated outlook on the launch of bitopertin and the favorable risk/reward scenario for DISC-0974. The recognition of a Commissioner’s National Priority Voucher further accelerates the review timeline for bitopertin, positioning the company to capitalize on market opportunities more swiftly.

Bears say

Disc Medicine Inc. faces significant challenges that contribute to a negative outlook on its stock. The company's pipeline, particularly the lead candidate bitopertin, may encounter hurdles related to regulatory approval and clinical efficacy, as concerns arise over the endpoints employed in Phase 3 trials, which could hinder the detection of a significant treatment benefit. Additionally, with limited cash reserves, the company may struggle to finance the development and commercialization of its products, further complicating its ability to advance its clinical programs efficiently.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.